Inflammatory Bowel Disease Clinical Trial
NCT number | NCT02222584 |
Other study ID # | 4-2014-0364 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | July 2014 |
Est. completion date | February 2018 |
Verified date | December 2018 |
Source | Yonsei University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Physical activity (PA) is beneficial in the prevention and management of chronic disease. However, few data exist regarding the level of PA in inflammatory bowel disease (IBD) and whether or not vigorous PA may have beneficial effects on patients' health. To evaluate the level of PA and the effect of PA on disease activity of patients with IBD. To evaluate the effect of PA on quality of life of patients with IBD.
Status | Completed |
Enrollment | 158 |
Est. completion date | February 2018 |
Est. primary completion date | February 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility |
Inclusion Criteria: - Age = 19 - patients with inflammatory bowel disease (Crohn's disease, Ulcerative Colitis, intestinal behcet's disease) Exclusion Criteria: - Age <19 - Patient who denied to response the survey questions - Patient who denied to enroll the survey research |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Severance Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Yonsei University |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | level of physical activity (PA) | Physical activity (PA) levels were assessed using the International PA Questionnaire. Based on self-reported frequency (day) and duration (hr) of physical activities, corresponding metabolic equivalent (MET-hr/wk) values were calculated to lowest PA, low PA, moderate PA and highest PA | 1 hour |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03278912 -
Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations
|
||
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05579392 -
A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis
|
N/A | |
Completed |
NCT03264690 -
Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD Patients
|
||
Recruiting |
NCT02861053 -
Inflammatory Bowel Disease : Could a Regular Physical Activity Reduce Patients Fatigue ?
|
N/A | |
Recruiting |
NCT02275676 -
Resting Energy Expenditure and Nutritional Status in IBD
|
N/A | |
Completed |
NCT02161640 -
Vascular Dysfunction in Paediatric IBD
|
N/A | |
Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
Completed |
NCT02503696 -
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
|
N/A | |
Completed |
NCT01933867 -
Water-aided Colonoscopy in Inflammatory Bowel Disease Patients
|
N/A | |
Completed |
NCT01852760 -
Assessment of Disease Activity in Ulcerative Colitis by Endoscopic Ultrasound
|
N/A | |
Completed |
NCT01860651 -
Web-based Monitoring in Children and Adolescents With Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT01692743 -
Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)
|
Phase 3 | |
Completed |
NCT01666535 -
Infliximab IBD Influenza Vaccine Study
|
N/A | |
Completed |
NCT01676324 -
FOCUS: The Future of Fecal Calprotectin Utility Study for the Diagnosis and Management of Inflammatory Bowel Disease (IBD)
|
N/A | |
Completed |
NCT01688557 -
Trial on Innovative Technologies in Colonoscopy
|
N/A | |
Completed |
NCT01981616 -
Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
|
Phase 1 | |
Completed |
NCT01557387 -
Real-time Diagnosis of Pseudopolyps During Colonoscopy
|
||
Completed |
NCT01221818 -
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A |